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Abstract
Background: Toxicity from chemotherapy is highly variable, unpredictable and results in substantial morbidity
and increased healthcare costs. New predictors of toxicity are required to improve the safety and efficacy of
chemotherapy. Inflammatory or B symptoms in lymphoma are associated with elevated plasma inflammatory
markers and predict worse treatment response and survival. Recent data suggest that systemic inflammation
results in reduced hepatic drug metabolism and increased toxicity from chemotherapy. We investigated whether
B symptoms were associated with greater toxicity in patients treated for non-Hodgkin lymphoma (NHL).
Methods: The British National Lymphoma Investigation compared two chemotherapy regimens in older patients
with aggressive NHL. Approximately 50% of patients had B symptoms. Demographic and toxicity data on 664
patients were analysed to identify predictors of toxicity by multivariate analysis, with particular reference to B
symptoms.
Results: Using univariate analyses, severe (grades 3–4) leucopenia, anaemia, thrombocytopenia, nausea and
vomiting and diarrhoea occurred more frequently in patients with B symptoms. The associations between B
symptoms and severe leucopenia (OR 1.7, p = 0.005) and anaemia (OR 2.3, p = 0.025) persisted after adjustment
for other prognostic factors in multivariate analyses. The use of granulocyte colony stimulating factor reduced
neutropenia in patients with both A and B symptoms.
Conclusion: For the first time and in a large NHL cohort we have shown that inflammatory symptoms are
independent predictors for myelosuppression from chemotherapy. These data will enable improved
prognostication for toxicity and provide individualisation of therapy in NHL and other tumours. These findings
also create the potential for strategies used prior to chemotherapy aimed at reducing systemic inflammation in
order to improve drug metabolism and reduce treatment-related toxicity.
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Background
Cancer chemotherapy produces variable and unpredicta-
ble toxicities, which can cause significant morbidity, occa-
sional mortality and result in substantial healthcare costs
due to increased requirement for toxicity-related hospital-
isation [1-3]. Non-Hodgkin lymphoma (NHL) is the fifth
most common cancer by incidence in both men and
women in the developed world [4] and is usually treated
with combination chemotherapy. Although regarded as a
chemotherapy-sensitive disease, over 50% of patients
with the diffuse large B cell variant will die of their disease.
The effective use of cancer chemotherapy is a balance
between adequate anti-tumour effect and manageable
normal tissue toxicities. There is evidence that dose reduc-
tion and delay for toxicity in NHL results in inferior
response rates and survival than when dose intensity is
maintained [5]. An improved ability to predict and/or
prevent toxicity would substantially improve outcomes in
NHL, and other malignancies.
The presence or absence of inflammatory or B symptoms
(fever > 38°C, weight loss > 5% or night sweats) is an
established negative prognostic factor in patients with
NHL. B symptoms are associated with increased plasma
levels of inflammatory proteins including C-reactive pro-
tein (CRP) [6] and cytokines such as interleukin-6 (IL-6)
[7]. Elevated inflammatory proteins have been shown to
correlate with other prognostic markers in NHL including
ECOG performance status, β2-microglobulin levels and
International Prognostic Index (IPI) [7,8]. In addition,
NHL patients with elevated plasma inflammatory markers
have lower response rates to chemotherapy and worse sur-
vival than those with normal levels [7-10].
The impact of inflammation on toxicity in NHL has not
been extensively investigated. Chemotherapy induced
toxicity is particularly relevant in NHL as many of the
patients are older and relatively frail, and toxicities may
lead to treatment interruption, dose reduction, major
morbidity necessitating hospitalization, and even treat-
ment-related death. There is evidence that loss of relative
dose intensity in NHL can compromise treatment out-
comes. For example, Kwak and colleagues reported that
NHL patients who received > 75% of planned doxoru-
bicin doses had markedly superior survival to those
receiving lesser doses [5]. Improved dose individualiza-
tion and avoidance of or reduction in the severity of tox-
icity would assist in maintaining dose intensity.
There is increasing evidence that a systemic inflammatory
response occurs frequently in patients with malignancy,
and is generally associated with worse clinical outcomes
(reviewed in [11]). Furthermore, the presence of raised
pro-inflammatory cytokines, including IL-6, has been
shown to negatively impact on hepatic drug metabolism
(reviewed in [12] and [13]). This concept is supported by
data which demonstrated that reductions in CYP3A4
activity in patients with advanced cancer were correlated
with increased plasma concentrations of IL-6 and CRP
[14]. This was associated with reduced clearance and
increased toxicity from docetaxel, a well-characterized
substrate for CYP3A4 [14,15]. Most cancer drugs are
metabolized by CYP3A4, including those used to treat
NHL.
These data suggested the hypothesis that cancer patients
with evidence of a tumour-induced inflammatory
response would experience greater chemotherapy-related
toxicity and worse treatment outcomes than patients
without such an inflammatory response. An obvious cir-
cumstance in which to test such an hypothesis is NHL,
due to the frequent presence and documentation of
inflammatory symptoms, and because reduced dose
intensity has an adverse prognostic impact in this condi-
tion. It is also timely to evaluate such a relationship as a
number of anti-inflammatory treatments have been devel-
oped recently, including monoclonal antibodies to
cytokines and cytokine receptors. These treatments could
potentially be used to reverse impaired cytotoxic drug
metabolism prior to commencement of chemotherapy.
A British National Lymphoma Investigation (BNLI) phase
III study compared the efficacy and safety of two chemo-
therapy regimens (cyclophosphamide, doxorubicin, vinc-
ristine and prednisone (CHOP) or mitoxantrone,
cyclophosphamide, etoposide, vincristine, bleomycin and
prednisolone (PMitCEBO)) with or without granulocyte
colony stimulating factor (G-CSF) in patients aged over 60
years with aggressive NHL [16]. This trial enrolled 784
patients of whom approximately 50% per arm had B
symptoms. In the current study we have reanalysed these
data to determine the prognostic impact of B symptoms
on toxicity.
Methods
The study procedures have been published previously
[16]. Briefly, consenting patients over 60 years of age diag-
nosed with diffuse large B cell lymphoma who had ade-
quate organ function and performance status were
randomised in a two by two fashion to receive chemother-
apy with either CHOP or PMitCEBO with or without G-
CSF. The study was approved by the human research eth-
ics committees of all participating centres.
Prediction of toxicity
Toxicity was recorded during all cycles of treatment in
regard to the worst grade of anaemia, leucopenia and
thrombocytopenia and the symptoms of nausea/vomit-
ing, diarrhoea, alopecia, mucositis, neuropathy and skin
rashes according to standard criteria (National CancerBMC Cancer 2009, 9:153 http://www.biomedcentral.com/1471-2407/9/153
Page 3 of 10
(page number not for citation purposes)
Institute Common Toxicity Criteria Version 3 (NCICTC v
3)-https://webapps.ctep.nci.nih.gov/webobjs/ctc/web
help/welcome_to_ctcae.htm).
Several prognostic variables were evaluated for their
impact on toxicity. These included age, sex, stage, per-
formance status, plasma lactate dehydrogenase concentra-
tion (LDH), type of chemotherapy used, presence of B
symptoms, presence of bone marrow involvement on
either aspirate or trephine, and use of G-CSF. The Interna-
tional Prognostic Index was not used in analyses because
it is a function of age, stage, performance status and LDH,
all of which were included separately in multivariate
modelling.
For some variables data were unavailable on moderately
large proportions of the original total of 784 patients; for
example 12.4% for LDH, 15.1% for bone marrow tre-
phine and 16.7% for bone marrow aspirate. Initially each
variable was checked against sex, age, disease stage, per-
formance status, type of chemotherapy and whether or
not GCSF was given to determine whether there were any
systematic differences in the distribution of missing data,
but none was found. In addition, other variables were
compared with the haematological toxicity measures in
the same manner. The only association found was that
patients with data missing on bone marrow aspirate and
trephine also tended to have data missing on haematolog-
ical toxicity. This may have arisen because of matters of
policy or availability of these tests in some centres from
which patients were drawn.
Patients in this study were all aged 60 years or older. Age
was dichotomized at 75 years because this is approxi-
mately the point at which normal mortality begins to take
effect in modern Western societies.
The statistical significance of differences in contingency
tables was assessed by the chi-squared test or Fisher's exact
test. Odds ratios (OR) for contingency tables and their 95
per cent confidence intervals (CI) were calculated by logis-
tic regression and their statistical significance was assessed
by the Wald test. The level for statistical significance was p
< 0.05. In multivariate modelling by logistic regression, all
predictor variables having an association with an outcome
variable with p < 0.1 were entered into an initial model
which was then reduced by successive elimination of var-
iables with p > 0.05. The provisional final model thus
obtained was further examined by re-entering/removing
every previously excluded variable separately until a
model containing only variables with p < 0.05 resulted.
Potential interactions between B symptoms and other var-
iables were evaluated but no such effects were identified.
Potential interactions among other variables were also
explored but none having any material influence on the
chosen final regression models were identified. As an
additional check regarding missing data, for each final
regression model, all patients who were excluded because
of missing data on any variable in the model were com-
pared with those who were included in relation to sex,
age, disease stage, performance status, type of chemother-
apy and whether or not GCSF was given, but no signifi-
cant differences were found. It was concluded that the
varying sub-sets of patients analysed were not unrepre-
sentative of the total pool of 784 patients. Analyses were
performed using SPSS Version 16 (SPSS Australasia Pty
Ltd).
Results
Of the 784 patients in the original study the following
were excluded sequentially: four with no information on
stage of disease, 20 with no information on B symptoms,
and 96 with no information on one or more of the hae-
matological toxicity measures (anaemia, leucopenia,
thrombocytopenia), leaving 664 patients for analysis,
most of whom had complete data on most variables ana-
lysed. The age and sex of patients, treatment groups, clin-
ical characteristics at randomization, maximum
haematological toxicity grades attained during treatment
and frequency of toxicity symptoms are shown in Tables 1
and 2. The presence of B symptoms was associated with
disease stages 3 or 4, performance levels 2–4, elevated
LDH and positive bone marrow assessments (Table 3). In
subsequent analyses patient age, disease stage, perform-
ance status and the toxicity variables were dichotomized
as shown in Table 4.
Leucopenia
In univariate analyses grade 3 or 4 leucopenia was signifi-
cantly associated with the presence of B symptoms occur-
ring in approximately 40% of patients without
inflammatory symptoms compared with 58% of those
with B symptoms (p < 0.001). Severe leucopenia also
occurred more frequently in patients aged 75 years or
older, having received PMitCEBO, having received GCSF,
disease stage 3 or 4, performance status level 2 or higher,
elevated LDH, positive bone marrow aspirate and positive
bone marrow trephine (Table 4). There was no associa-
tion with sex. The association between B symptoms and
leucopenia persisted (OR 1.7, 95% CI 1.2–2.4) in multi-
variate analysis after adjustment for age, performance sta-
tus, bone marrow involvement, type of chemotherapy
and receipt of GCSF, the latter having a protective effect
(Table 5).
Anaemia
In univariate analyses grade 3 or 4 anaemia was signifi-
cantly associated with the presence of B symptoms occur-
ring in 10% of patients with B symptoms compared with
5% without (p = 0.011). Severe anaemia was also associ-BMC Cancer 2009, 9:153 http://www.biomedcentral.com/1471-2407/9/153
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ated with diminished performance status, elevated LDH
and a positive bone marrow aspirate (Table 4). Patients
who had received GCSF were also more likely to experi-
ence grade 3 or 4 anaemia. There were no statistically sig-
nificant associations with the other variables considered.
The association between B symptoms and anaemia per-
sisted in a reduced logistic regression model after adjust-
ment for receipt of GCSF and elevated LDH (OR 2.3, 95%
CI 1.1–4.7 – Table 5).
Thrombocytopenia
Grade 3 or 4 thrombocytopenia was associated with the
presence of B symptoms in univariate analysis and
occurred in 6% and 14% of patients with A and B symp-
toms, respectively (p < 0.001, Table 4). Other features
associated with thrombocytopenia were age 75 or older,
stage 3 or 4 disease, level 3 or 4 performance status, ele-
vated LDH, positive bone marrow aspirate and positive
bone marrow trephine. There were marginally non-signif-
icant associations with type of chemotherapy and receipt
of GCSF, but no association with sex. In multivariate anal-
ysis, however, the significant association between B symp-
toms and thrombocytopenia was not sustained after
adjustment for performance status, LDH, bone marrow
trephine and type of chemotherapy (Table 5).
Non-haematological toxicity
There were no associations between B symptoms and
mucositis, neuropathy or skin rashes. In univariate analy-
ses moderate to very severe (grades 2–4) nausea and vom-
Table 1: Distribution of patients by baseline clinical variables.
Variable Category Number (%)
N = 664
Sex Female 311 (46.8)
Male 353 (53.2)
Age Less than 75 years 496 (74.7)
75 years or older 168 (25.3)
Chemotherapy CHOP 334 (50.3)
PMitCEBO 330 (49.7)
GCSF No 330 (49.7)
Yes 334 (50.3)
Stage I 70 (10.5)
II 176 (26.5)
III 193 (29.1)
IV 225 (33.9)
B symptoms No 311 (46.8)
Yes 353 (53.2)
ECOG Performance status 0 206 (31.0)
1 264 (39.8)
2 131 (19.7)
3 39 (5.9)
4 13 (2.0)
No data 11 (1.7)
Plasma LDH concentration (mU/L)
Normal (0.2–0.5) 216 (32.5)
Elevated (> 0.5) 381 (57.4)
No data 67 (10.1)
Bone marrow aspirate Not involved 508 (76.5)
Involved 57 (8.6)
No data 99 (14.9)
Bone marrow trephine Not involved 487 (73.3)
Involved 89 (13.4)
No data 88 (13.3)BMC Cancer 2009, 9:153 http://www.biomedcentral.com/1471-2407/9/153
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iting (21% vs 15%) and diarrhoea (21% vs 12%) were
significantly more common among patients with B symp-
toms (Table 6). However the associations between B
symptoms and nausea and vomiting and diarrhoea disap-
peared after adjustment for other variables independently
associated with these symptoms (Table 7).
Response and survival
There was no statistically significant difference in either
response rates or survival for patients with or without B
symptoms.
Discussion
These data demonstrate for the first time and in a large
patient cohort that the presence of inflammatory (B)
symptoms is an independent predictor of increased inci-
dence of severe leucopenia and anaemia in patients with
malignancy, in this case high risk, intermediate grade
non-Hodgkin lymphoma. Although B symptoms were
associated with an increased risk of thrombocytopenia,
nausea and vomiting and diarrhoea on univariate analy-
sis, these associations were not supported on multivariate
analysis.
The study has some limitations. Firstly, it was an
unplanned reanalysis of prospectively collected data, and
the presence of inflammation was only assessed clinically
as correlative blood samples for measurement of inflam-
matory proteins were not available. In addition, it was not
possible to assess the impact of B symptoms on the inci-
dence of neutropenia, febrile neutropenia, toxicity related
hospitalisation, treatment related death and dose delay or
reduction, as these data had not been reliably recorded.
Such associations and correlation with plasma inflamma-
tory markers should be evaluated in future studies. How-
ever, an 18% increase (40% vs 58%) in the incidence of
grades 3 and 4 leucopenia, which was worse in patients
with inflammatory symptoms is highly clinically signifi-
cant and likely to impact on such outcomes.
This study was principally undertaken to provide a clinical
"proof of principle" of our previous pre-clinical and clini-
cal findings that the presence of an inflammatory
response predicts for slower hepatic clearance of cytotoxic
drugs and increased toxicity. The data will not have a
major immediate impact on the management of patients
with NHL, as prophylactic G-CSF is already routinely used
in this condition, and our data confirm that this provides
a protective effect against leucopenia. Also, in this cohort,
the presence of inflammatory symptoms did not adversely
impact on survival, which again raises questions about the
immediate clinical significance of our findings. However,
this may have been due in part to our desire to include
only patients on whom full data sets were available for the
assessment of toxicity and could have excluded patients
Table 2: Overall toxicity from chemotherapy in selected cohort.
Variable Category Number (%)
N = 664
Anaemia stage 0 116 (17.5)
1 241 (36.3)
2 259 (39.0)
3 39 (5.9)
4 9 (1.4)
Leucopenia stage 0 171 (25.8)
1 70 (10.5)
2 96 (14.5)
3 154 (23.2)
4 173 (26.1)
Thrombocytopenia 0 503 (75.8)
1 51 (7.7)
2 45 (6.8)
3 33 (5.0)
4 32 (4.8)
Mucositis 0 347 (52.3)
1 137 (20.6)
2 98 (14.8)
3 17 (2.6)
4 3 (0.5)
No data 62 (9.3)
Nausea/vomiting 0 329 (49.5)
1 168 (25.3)
2 68 (10.2)
3 39 (5.9)
4 5 (0.8)
No data 55 (8.3)
Diarrhoea 0 434 (65.4)
1 74 (11.1)
2 50 (7.5)
3 45 (6.8)
4 7 (1.1)
No data 54 (8.1)
Neuropathy 0 318 (47.9)
1 192 (28.9)
2 77 (11.6)
3 26 (3.9)
40
No data 51 (7.7)
Skin rash 0 521 (78.5)
1 50 (7.5)
2 27 (4.1)
3 7 (1.1)
4 2 (0.3)
No data 57 (8.6)BMC Cancer 2009, 9:153 http://www.biomedcentral.com/1471-2407/9/153
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who experienced early disease progression. Furthermore,
multiple previous investigators have established that B
symptoms are associated with worse progression free and
overall survival in NHL [6-10].
As discussed above, B symptoms are indicators of a sys-
temic inflammatory response and have been associated
with elevated plasma concentrations of CRP and pro-
inflammatory cytokines [6,9,10]. Moreover, clinical stud-
ies with anti IL-6 monoclonal antibody in patients with
lymphoproliferative conditions resulted in reductions in
CRP concentrations and improved clinical outcome [17].
There is substantial pre-clinical and clinical evidence from
cancer and other inflammatory diseases, that hepatic drug
clearance is reduced in the presence of a systemic inflam-
matory response [18-20]. A number of agents used in the
management of NHL are metabolized by the liver includ-
ing doxorubicin, cyclophosphamide and vincristine. As
over 50% of all prescribed medications, including many
cytotoxic agents, are metabolized by CYP3A4, this may be
a significant source of pharmacokinetic and toxicity varia-
bility to anticancer agents [13,21-24].
The effects of cancer on hepatic drug metabolism have
been recently clarified. Rivory and colleagues demon-
strated that cancer patients with elevated acute phase pro-
teins, including CRP and alpha-1 acid glycoprotein
(AAGP), had reduced CYP3A4 function as determined by
the erythromycin breath test [14]. The elevated plasma
CRP concentrations were associated with increased
plasma concentrations of IL-6. In addition, elevated levels
of CRP were associated with reduced plasma clearance
and increased toxicity following treatment with docetaxel,
a CYP3A4 substrate [15]. By utilising a regulatory trans-
genic reporter mouse model of human CYP3A4, Charles
and colleagues demonstrated that the presence of tumour
resulted in down-regulation of the CYP3A4, which corre-
lated with a systemic acute phase response. Furthermore,
IL-6 expression was localised within the tumour, suggest-
ing that the tumour or its associated stroma was the source
of the increased circulating IL-6 noted in this model. As a
result of this study a mechanistic link was suggested
between tumour-derived cytokines and impaired drug
metabolism [25]. Furthermore, in data from the same
models, Sharma and colleagues demonstrated significant
reductions in the expression of a number of drug trans-
porters in the livers of tumour bearing mice compared to
control animals, suggesting a global reduction in hepatic
drug handling in the presence of malignancy.
These data make it likely that cytokines responsible for the
B symptoms in NHL are also causing reduced hepatic drug
clearance, resulting in the increased toxicity documented
in the current study. This finding has a number of impor-
tant clinical and research implications for NHL and cancer
in general. Firstly, it means that we have a useful marker
for increased toxicity in NHL. Although a number of prog-
nostic indices have been used in NHL most have been
used to predict for response and survival rather than tox-
icity. The ability to identify patients at increased risk of
myelosuppression and infection will permit increased sur-
veillance and possibly increased use of prophylactic anti-
biotics. Furthermore, the prognostic utility of B symptoms
could be enhanced by measuring plasma proteins includ-
Table 3: Association between B symptoms and clinical variables.
Variable Category n B symptoms present p
Sex Female 311 169 (54.3) 0.577
Male 353 184 (52.1)
Age < 75 years 496 261 (52.6) 0.631
GE 75 years 168 92 (54.8)
Stage Stage 0–2 246 94 (38.2) < 0.001
Stage 3–4 418 259 (62.0)
Performance status Level 0–1 470 210 (44.7) < 0.001
Level 2–4 183 137 (74.9)
LDH Normal 216 95 (44.0) < 0.001
Elevated 381 223 (58.5)
Bone marrow aspirate Negative 508 266 (52.4) 0.040
Positive 57 38 (66.7)
Bone marrow trephine Negative 487 246 (50.5) < 0.001
Positive 89 62 (69.7)BMC Cancer 2009, 9:153 http://www.biomedcentral.com/1471-2407/9/153
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ing CRP or cytokines such as IL-6. The availability of mul-
tiplex bead cytokine analyses that permit simultaneous
measurement of multiple cytokines should facilitate such
research. These findings may also be applicable to other
malignancies where it is likely that inflammation is
responsible for a significant proportion of the variability
in toxicity from chemotherapy. However, as overall sur-
vival has consistently been lower in patients with elevated
inflammatory markers [7-10] it would be potentially haz-
ardous to manage an increased risk of toxicity by dose
reduction as this could further compromise response and
survival. It may also be possible to use inflammatory
markers to more appropriately guide the use of colony
stimulating factors in patients with solid tumours.
In addition to providing prognostic information, the
inflammatory proteins provide a potential target for novel
therapies aimed at reversing the inflammatory effects,
improving drug handling and reducing toxicity. A number
of antibodies have been developed to target pro-inflam-
matory cytokines, including TNF-α, IL-6 and IL-6 recep-
tor, and these should be investigated for their potential to
reverse tumour-associated impairment of drug metabo-
lism. There are preliminary data to suggest that this
approach might also help to overcome tumour resistance.
However, these data require confirmation in prospective
clinical studies that also involve the collection of plasma
for measurement of acute phase proteins and cytokines.
Conclusion
This study shows that patients with aggressive non-Hodg-
kin lymphoma who have B symptoms experience signifi-
cantly more myelosuppression than those without
inflammatory symptoms. The toxicities were less in
patients who had received G-CSF. These data support the
hypothesis that patients with a cancer induced inflamma-
tory reaction have reduced hepatic metabolism of cyto-
toxic drugs which results in the increased toxicity. These
results might help explain some of the substantial inter-
patient differences in toxicity from chemotherapy.
Table 4: Patients with grade 3 or 4 anaemia, leucopenia or thrombocytopenia by demographic, treatment and clinical variables. 
Number (per cent).
Variable Category n Grade 3/4 leucopenia p Grade 3/4 anaemia p Grade 3/4 
thrombocytopenia
p
B symptoms No 311 124 (39.9) < 0.001 14 (4.5) 0.011 17 (5.5) < 0.001
Yes 353 203 (57.5) 34 (9.6) 48 (13.6)
Sex Female 311 159 (51.1) 0.363 25 (8.0) 0.450 33 (10.6) 0.504
Male 353 168 (47.6) 23 (6.5) 32 (9.1)
Age < 75 years 496 226 (45.6) 0.001 33 (6.7) 0.324 40 (8.1) 0.010
≥ 75 years 168 101 (60.1) 15 (8.9) 25 (14.9)
Chemotherapy CHOP 334 129 (38.6) < 0.001 27 (8.1) 0.392 40 (12.0) 0.056
PMitCEBO 330 198 (60.0) 21 (6.4) 25 (7.6)
GCSF No 330 184 (55.8) < 0.001 14 (4.2) 0.003 25 (7.6) 0.056
Yes 334 143 (42.8) 34 (10.2) 40 (12.0)
Stage Stage 0–2 246 99 (40.2) < 0.001 14 (5.7) 0.240 11 (4.5) < 0.001
Stage 3–4 418 228 (54.5) 34 (8.1) 54 (12.9)
Performance status Level 0–1 470 197 (41.9) < 0.001 27 (5.7) 0.012 25 (5.3) < 0.001
Level 2–4 183 125 (68.3) 21 (11.5) 39 (21.3)
LDH (mU/L) Normal 216 96 (44.4) 0.038 7 (3.2) 0.008 5 (2.3) < 0.001
Elevated 381 203 (53.3) 34 (8.9) 52 (13.6)
Bone marrow aspirate Negative 508 248 (48.8) 0.005 31 (6.1) 0.046* 45 (8.9) 0.004
Positive 57 39 (68.4) 8 (14.0) 12 (21.1)
Bone marrow Negative 487 228 (46.8) 0.001 30 (6.2) 0.083 40 (8.2) 0.001
Trephine Positive 89 58 (65.2 10 (11.2) 18 (20.2)
* Fisher exact pBMC Cancer 2009, 9:153 http://www.biomedcentral.com/1471-2407/9/153
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Table 5: Logistic regressions for association between leucopenia, anaemia and thrombocytopenia and B symptoms and other potential 
predictor variables.
Univariate OR# p Multivariate OR# p
(95% CI@)( 9 5 %  C I @)
Leucopenia *
B symptoms present 2.0 (1.5–2.8) < 0.001 1.7 (1.2–2.4) 0.005
Performance status level 2–4 3.0 (2.1–4.3) < 0.001 2.2 (1.5–3.3) < 0.001
Bone marrow aspirate positive 2.3 (1.3–4.1) 0.006 2.2 (1.2–4.0) 0.015
Age 75 years or older 1.8 (1.3–2.6) 0.001 2.1 (1.4–3.1) < 0.001
PMitCEBO given 2.4 (1.7–3.3) < 0.001 2.1 (1.5–3.0) < 0.001
GCSF given 0.6 (0.4–0.8) 0.001 0.5 (0.4–0.8) 0.001
Bone marrow trephine positive 2.1 (1.3–3.4) 0.002 -
Stage 3 or 4 1.8 (1.3–2.5) < 0.001 -
LDH elevated 1.4 (1.02–2.0) 0.038 -
Anaemia **
B symptoms present 2.3 (1.2–4.3) 0.013 2.3 (1.1–4.7) 0.025
LDH elevated 2.9 (1.3–6.7) 0.011 2.6 (1.1–6.1) < 0.001
GCSF given 2.6 (1.3–4.9) 0.004 2.3 (1.1–4.5) 0.020
Bone marrow aspirate positive 2.5 (1.1–5.8) 0.030 -
Performance status level 2–4 2.1 (1.2–3.9) 0.013 -
Bone marrow trephine positive 1.9 (0.9–4.1) 0.088 -
Thrombocytopenia ***
B symptoms present 2.7 (1.5–4.8) 0.001 -
Performance status level 2–4 4.8 (2.8–8.2) < 0.001 4.8 (2.5–9.2) < 0.001
LDH elevated 6.7 (2.6–17.0) < 0.001 4.0 (1.5–10.4) 0.005
Bone marrow trephine positive 2.8 (1.5–5.2) 0.001 2.9 (1.4–5.8) 0.003
PMitCEBO given 0.6 (0.4–1.0) 0.058 0.5 (0.3–0.9) 0.032
Stage 3 or 4 3.2 (1.6–6.2) 0.001 -
Bone marrow aspirate positive 2.7 (1.4–5.6) 0.005 -
Age 75 years or older 2.0 (1.2–3.4) 0.011 -
GCSF given 1.7 (1.0–2.8) 0.058 -
* The multivariate model is for 560 patients with complete data on all variables included in it.
** The multivariate model is for 597 patients with complete data on all variables included in it.
*** The multivariate model is for 522 patients with complete data on all variables included in it.
# Odds ratio
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Table 6: Patients with moderate to very severe nausea/vomiting or diarrhoea by demographic, treatment and clinical variables. 
Variable Category Nausea/vomiting p Diarrhoea p
B symptoms No 43/285 (15.1) 0.048 34/284 (12.0) 0.003
Yes 69/324 (21.3) 68/326 (20.9)
Sex Female 68/285 (23.9) 0.001 54/286 (18.9) 0.179
Male 44/324 (13.6) 48/324 (14.8)
Age < 75 years 84/453 (18.5) 0.869 65/452 (14.4) 0.009
GE 75 years 28/156 (17.9) 37/158 (23.4)
Chemotherapy CHOP 72/315 (22.9) 0.003 58/313 (18.5) 0.219
PMitCEBO 40/294 (13.6) 44/297 (14.8)
Stage Stage 0–2 40/227 (17.6) 0.705 30/225 (13.3) 0.086
Stage 3–4 72/382 (18.8) 72/385 (18.7)
Performance status Level 0–1 60/430 (14.0) < 0.001 50/429 (11.7) < 0.001
Level 2–4 48/169 (28.4) 50/171 (29.2)
Number (per cent).
Table 7: Logistic regression for association between moderate to very severe nausea and vomiting and diarrhoea and B symptoms and 
other potential predictor variables.
Univariate OR#
(95% CI@)
p Multivariate OR#
(95% CI@)
p
Nausea and vomiting*
B symptoms present 1.5 (1.0–2.3) 0.049 -
Performance status level 2–4 2.4 (1.6–3.8) < 0.001 2.6 (1.6–4.0) < 0.001
Male sex 0.5 (0.3–0.8) 0.001 0.5 (0.3–0.7) 0.001
PMitCEBO given 0.5 (0.3–0.8) 0.004 0.5 (0.3–0.8) 0.003
Diarrhoea**
B symptoms present 1.9 (1.2–3.0) 0.004 -
Performance status level 2–4 3.1 (2.0–4.9) < 0.001 3.2 (2.0–5.0) < 0.001
Age 75 years or older 1.8 (1.2–2.9) 0.009 1.9 (1.2–3.1) 0.006
Stage 3 or 4 1.5 (0.9–2.4) 0.088 -
* The multivariate model is for 599 patients with complete data on all variables included in it.
** The multivariate model is for 600 patients with complete data on all variables included in it.
# Odds ratio
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